TITLE

Mean changes versus dichotomous definitions of improvement

AUTHOR(S)
Anderson, Jennifer J.
PUB. DATE
February 2007
SOURCE
Statistical Methods in Medical Research;Feb2007, Vol. 16 Issue 1, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
In recent years, when reporting the results of clinical trials for chronic disease, including rheumatologic conditions, use has been made of dichotomous definitions of improvement, but it is to be expected that continuous definitions would offer improved discrimination between treatment groups. Nevertheless, a well-constructed dichotomous outcome (usually a composite) has advantages of clinical sense and specificity and may, under a variety of realistic conditions, have power that closely approximates that of standard continuous outcome measures. This has been seen for established dichotomous outcome definitions for two rheumatologic conditions, rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Simulation studies performed using multivariate normal generated data that approximates actual trial data for each of RA and AS patients demonstrate the relative power of several dichotomous and continuous outcomes in realistic situations for each of RA and AS. Although the continuous outcomes are typically more powerful than the dichotomous ones, there are some situations in which the power of a well-defined dichotomous outcome approaches or even exceeds that of a continuous outcome based on mean change.
ACCESSION #
25219057

 

Related Articles

  • CLINICAL UPDATES.  // BMJ: British Medical Journal;2/20/2016, Vol. 352 Issue 8045, p281 

    This section offers news briefs relevant to clinical medicine in Great Britain as of February 2016 including the use of tumor necrosis factor-alpha for the treatment of ankylosing spondylitis and the recommended use of nintedanib for idiopathic pulmonary fibrosis.

  • Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Kay, Jonathan; Rahman, Mahboob U. // Core Evidence;2009, Vol. 4 Issue 1, p159 

    Introduction: The introduction of tumor necrosis factor-α (TNF-α) inhibitors represented a significant advance in the management of rheumatoid arthritis (RA) and other chronic inflammatory diseases. Although three TNF-α inhibitors have been approved for the treatment of RA by the US...

  • Clinical and demographic findings of patients with rheumatoid arthritis and ankylosing spondylitis treated in a tertiary care center in Turkey. CEMEROĞLU, Özlem; YAŞAR, Zeynep Sıla; SAĞLAM, Mustafa; ÇAKIRBAY, Haşim // Turkish Journal of Medical Sciences;2014, Vol. 44 Issue 4, p595 

    Background/aim: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are 2 common rheumatic diseases that are frequent causes of disability. In this descriptive study, demographic, clinical, and laboratory findings of patients with RA and AS being followed in a tertiary care center in...

  • A CCR6 variant strongly associated with rheumatoid arthritis in two populations is not associated with ankylosing spondylitis. Cohen, Carla; Karaderi, Tugce; Pointon, Jennifer; Wordsworth, B. // Rheumatology International;Sep2013, Vol. 33 Issue 9, p2443 

    A letter to the editor is presented in response to the article "A CCR6 variant strongly associated with rheumatoid arthritis in two populations is not associated with ankylosing spondylitis" by Cohen and colleagues in the previous issue.

  • RA and AS significant economic burden in Turkey.  // PharmacoEconomics & Outcomes News;5/26/2012, Issue 654, p8 

    The article discusses a research study which showed the significant economic burden of the direct and indirect costs of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in Turkey.

  • Rheumatoid arthritis and ankylosing spondylitis occurring together. Fallet, Georges H.; Mason, Michael; Berry, Hedley; Mowat, Alastair G.; Boussina, Iradj; Gerster, Jean-Charles // British Medical Journal;4/3/1976, Vol. 1 Issue 6013, p804 

    Examines the occurrence of the rheumatoid arthritis and ankylosing spondylitis together on patients condition. Importance of natural history and treatment of the condition; Concepts on the definition of the rheumatoid arthritis and ankylosing spondylitis; Reconsideration on the basic concepts...

  • Golimumab: A human anti-TNF-alpha monoclonal antibody for the treatment of autoimmune joint diseases. Phung, Olivia J.; Coleman, Craig I. // Formulary;Sep2009, Vol. 44 Issue 9, p264 

    Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), in clinical trials, subcutaneous (SC) golimumab injected every 4 weeks...

  • Etanercept. McCormack, Paul L.; Wellington, Keri // BioDrugs;2004, Vol. 18 Issue 3, p199 

    Etanercept is a dimeric fusion protein based on the p75 tumor necrosis factor (TNF) receptor. It binds to TNF and blocks its biological activity. Subcutaneous etanercept is effective in the treatment of rheumatoid arthritis, psoriatic arthritis, and polyarticular-course juvenile rheumatoid...

  • PREPARATION AND EVALUATION OF PARACETAMOL BY SOLID DISPERSION TECHNIQUE. Akiladevi, D.; Shanmugapandiyan, P.; Jebasingh, D.; Basak, Sachinandhan // International Journal of Pharmacy & Pharmaceutical Sciences;Jan2011, Vol. 3 Issue 1, p188 

    Paracetamol is a potent anti-inflammatory analgesic agent indicated for acute and chronic treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondylytis. Paracetamol is poor water soluble and may show dissolution limited absorption. The solid dispersion of paracetamol by physical...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics